Becky Bole
Psychiatric/Mental Health · Nampa, IDNPI 1043621576
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 287 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,836 and has fallen 73.5% since, to $487 in 2025. Among psychiatric/mental health clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 287 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$803
- Alkermes, Inc.$724
- Otsuka America Pharmaceutical, Inc.$717
- Supernus Pharmaceuticals, Inc.$421
- Johnson & Johnson$414
- Corium, LLC$311
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,586100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 68 | $803 |
| Alkermes, Inc. | 27 | $724 |
| Otsuka America Pharmaceutical, Inc. | 45 | $717 |
| Supernus Pharmaceuticals, Inc. | 21 | $421 |
| Johnson & Johnson | 12 | $414 |
| Corium, LLC | 14 | $311 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $273 |
| Tris Pharma Inc | 9 | $266 |
| Lundbeck LLC | 12 | $221 |
| Corcept Therapeutics | 11 | $214 |
| Teva Pharmaceuticals USA, Inc. | 9 | $194 |
| Eisai Inc. | 10 | $154 |
| E.r. Squibb & Sons, L.L.C. | 2 | $139 |
| Vanda Pharmaceuticals Inc. | 6 | $105 |
| Axsome Therapeutics, Inc. | 3 | $102 |
| Antares Pharma, Inc. | 4 | $96 |
| Idorsia Pharmaceuticals US Inc | 4 | $76 |
| Novo Nordisk | 2 | $48 |
| Lilly USA, LLC | 2 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Indivior Inc. | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 2 | $31 |
| Bayer | 2 | $30 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Braeburn Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Abbott | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$423
- VIVITROL$122
- Azstarys$117
- Dyanavel XR$111
- SPRAVATO$107
- Dayvigo$104
- INVEGA SUSTENNA$100
How this compares
$5,586 in reported general payments places this provider in the 90th percentile of 221 psychiatric/mental health providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 16 | $42,736 |
| VraylarCariprazine Hcl | 25 | $37,024 |
| CaplytaLumateperone Tosylate | 20 | $33,463 |
| RexultiBrexpiprazole | 20 | $27,723 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 89 | $24,410 |
| Paliperidone ErPaliperidone | 13 | $7,952 |
| DayvigoLemborexant | 23 | $7,489 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 69 | $5,926 |
| Aripiprazole | 51 | $5,405 |
| Lisdexamfetamine Dimesylate | 22 | $4,817 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 29 | $2,912 |
| Bupropion XlBupropion Hcl | 127 | $1,589 |
| Lubiprostone | 12 | $1,016 |
| Methylphenidate Hcl | 23 | $958 |
| Olanzapine | 45 | $824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $414 | $42,73616 claims |
| AbbVieVraylar | $803 | $37,02425 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $273 | $33,46320 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $717 | $27,72320 claims |
| Eisai Inc.Dayvigo | $154 | $7,48923 claims |
| Lilly USA, LLCOlanzapine | $45 | $82445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 221 psychiatric/mental health providers in Idaho.
Other psychiatric/mental health in Nampa
- Scott WatkinsNampa$11K
- Matthew FowlerNampa$3K
- Jason MartinIdaho Falls$78K
- Misti NewsonBoise$56K
- Jared PetrickCoeur D Alene$32K
- Carey CrillBoise$19K
- Deborah RushMeridian$13K
- Ashley CroftCaldwell$13K
- Julie SchraderBoise$9K
- Susan DayBoise$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.